Cutaneous T-cell lymphoma is a heterogeneous group of T-cell neoplasms, of which mycosis fungoides and Sezary syndrome are the most common. The prognosis depends on the stage of the disease. The early stage follows a protracted course with a five-year disease-specific survival of greater than 95% and is treated with skin-directed topical therapies, phototherapy, and oral drugs like methotrexate. Advanced disease has a five-year overall survival of less than 25% and requires management by systemic chemotherapeutic agents. This review article is the second part out of the two covering the staging, prognosis, and treatment from a dermatologist's perspective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.25259/IJDVL_754_2023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
J Cutan Med Surg
March 2025
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of cutaneous T-cell lymphoma with numerous topical and systemic therapies. Early-stage MF can be managed with topical corticosteroids, mechlorethamine, and phototherapy. However, patients are often non-responsive to topical therapies, thus requiring systemic therapies.
View Article and Find Full Text PDFClinical Characteristics, Management and Long-Term Outcomes of 180 Patients With Early-Stage Mycosis Fungoides at a Tertiary Centre-A 34-Year Retrospective Study.
Australas J Dermatol
March 2025
Department of Dermatology, Ankara University Faculty of Medicine, Ankara, Turkey.
Background: Mycosis fungoides (MF) is the commonest form of primary cutaneous T-cell lymphoma. Progression is slow, with frequent relapses. Data for predicting early-stage MF progression and recurrence are inadequate.
View Article and Find Full Text PDFCondensed low-dose total skin electron beam therapy for mycosis fungoides: an institutional retrospective review and subgroup analysis of patients with large cell transformation.
Arch Dermatol Res
March 2025
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Low-dose total skin electron beam therapy (TSEBT) is an effective treatment option for mycosis fungoides (MF) with proven palliative effects and reduced toxicity. Presented is an institutional analysis of survival/response rate and quality of life for MF patients with subgroup analysis of those possessing pathologic large cell transformation (LCT). This is a single institutional retrospective review of patients with mycosis fungicides treated from 2014 to 2023 with low-dose TSEBT.
View Article and Find Full Text PDFUnveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.
Curr Oncol Rep
March 2025
1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "Andreas Sygros" Hospital for Skin & Venereal Diseases, Athens, Greece.
Purpose Of Review: Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies.
Recent Findings: Recent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix.
Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes.
Cancer Med
March 2025
Huntsman Cancer Institute, Salt Lake City, Utah, USA.
Background: We investigated mental health diagnoses (MHDs) in mycosis fungoides (MF) patients compared to the general population, evaluated risk factors, and studied survival outcomes in a large population database.
Methods: MF patients from the Utah Cancer Registry diagnosed from 2001 to 2014 were matched with up to five general population individuals from the Utah Population Database. MHDs were retrospectively tracked in both populations (median follow-up = 6.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!